We were delighted to speak with Teresa Quattrin (University at Buffalo, Oishei Children’s Hospital) at virtual EASD 2020 to talk about the treatment landscape for children with type 1 diabetes and what the future holds.
Speaker Disclosures: Tersea Quattrin discloses the following: Consultant to Janssen Research & Development
Clinical Trial, Principal Investigator at the Buffalo site: Janssen, Provention Bio, Inc., OPKO Biologics Ltd. and Ascendis.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the European Association for the Study of Diabetes (EASD) 2020.
